Search

Background: The surgical outcomes for younger patients with non‐small cell lung cancer (NSCLC) remain uncertain. The aim of this study was to investigate the clinical features long‐term survival outcomes in younger individuals with NSCLC following surgery. Methods: We queried the Surveillance, Epidemiology, and End Results database from 2010 to 2017, selecting all pathologically confirmed NSCLC cases that underwent cancer‐directed surgery. Younger patients were defined as those aged 18–50 years, while older patients were 51–80 years. Propensity score matching (PSM) was implemented to mitigate selection bias. Overall survival (OS) and lung cancer‐specific survival (LCSS) were compared using the Kaplan–Meier method. Results: Among the 33 586 treated surgically patients, 2223 (6.6%) were young. Compared to the older group, younger patients had a higher frequency of female gender, non‐white ethnicity, carcinoid tumors, stage IV disease, pneumonectomy, and postoperative adjuvant therapies. The 5‐year OS rates were significantly higher for younger patients (79.3% vs. 62.0%; p < 0.001), as were the 5‐year LCSS rates (82.4% vs. 71.8%; p < 0.001). Post‐PSM, younger patients consistently demonstrated significantly better OS and LCSS. Further stage‐specific analysis revealed significantly improved 5‐year OS rates at each stage and superior 5‐year LCSS for stages I–II among younger patients. However, there was no statistically significant difference in LCSS for stages III–IV. Conclusions: Overall, younger patients with NSCLC treated surgically exhibit superior OS and LCSS compared to their older counterparts, although no statistically significant difference in LCSS for stages III–IV was observed between the two age groups. [ABSTRACT FROM AUTHOR]

Background: The risk of lung cancer (LC) increases with an older age and is most frequently diagnosed among patients aged 65–74 years with an increasing women ratio over the years in the United States (US). Aim: This study aimed to demonstrate the age and gender distribution of Turkish LC patients at diagnosis over the past 10 years. Material and Methods: A total of 5,201 LC patients who had been admitted to the Institute of Oncology, a tertiary referral center, from January 2011 to December 2020 were included in the study. Results: The median age at diagnosis was 62 years. This was 9 years younger than that of the US patients according to surveillance, epidemiology, and end results program data from 2015 to 2019, showing that the median age at diagnosis was 71 years. The distribution curve of the age-specific incidence ratios significantly shifted to the left compared to the American data. The majority of the patients were men (79.2%); women were 20.8%. These values were quite different from the US patients; the distribution of gender was nearly identical, with 51.8% for men and 48.2% for women according to American Cancer Society data from 2011 to 2020. The changes in the ratios of Turkish and US LC patients by sex were identical over the years; although the proportion of men has been in a downtrend, the proportion of women has been in an uptrend in both countries. Conclusion: Turkish LC patients are diagnosed at younger ages and male-dominant compared to LC patients from the US, and this portends a significant health problem. Therefore, efforts to quit smoking must be increased. [ABSTRACT FROM AUTHOR]

Background: The incidence of breast cancer (BC) has been on the rise over the last decades in the USA, and it is most frequently diagnosed among women aged 65-74 years., Aims: The aim of this study was to demonstrate the median age of BC at diagnosis and the age-specific incidence ratios of Turkish BC patients over the last 10 years., Methods: A total of 6009 Turkish BC patients who had been admitted to the Institute of Oncology, a tertiary referral center, from January 2011 to December 2020 were included in the study., Results: The median age at diagnosis was 49 years. This was 14 years younger than that of the US patients according to SEER data from 2014 to 2018 showing that the median age at diagnosis was 63 years. The distribution curve of the age-specific incidence ratios significantly shifted to the left compared to the American data., Conclusions: Turkish BC patients are diagnosed at younger ages than BC patients in developed countries, and this portends a significant health problem. Therefore, it is important and vital that society be educated about the disease without any further delay and screening programs should be instated effectively and extensively from the age of forties., (© 2022. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland.)